Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › retinal degeneration

Retinal degeneration

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for retinal degeneration

8 trials tracked for retinal degeneration: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 4 citations.

8Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 1 Phase 1 3 Other / NA 3
  1. Phase 3 Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD Completed · 4 cited
  2. Phase 2 Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) Completed
  3. Phase 1 Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration Completed
  4. Phase 1 Intravitreal Mesenchymal Stem Cell Transplantation in Advanced Glaucoma. Completed
  5. Phase 1 Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy Completed
  6. N/A Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification Completed
Show 2 more trials
  1. N/A BCI and Evaluation of Visual and Task Performance in Subjects With Eye Diseases Completed
  2. N/A A Multi-Center Study of Reading Rehabilitation in Macular Disease Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Retinal degeneration: what the trials found

Clinical investigations into retinal degeneration have evaluated the safety and physiological impacts of various interventions, including brolucuzumab (6 mg IVT) 1 and RN6G [3, 5].

In studies involving RN6G, measurements were taken regarding plasma Amyloid (A) Beta concentrations. Specifically, for A Beta (1-40), percent changes from baseline were recorded at multiple intervals up to 304/ET, while A Beta (1-42) also showed measured percent changes 3. Additionally, Prothrombin Time (PT) International Normalized Ratio (INR) was monitored over a period of 304/ET, showing values ranging from -0.047 to 1.017 3.

Recent results — preliminary, needs further review

  • Aflibercept is currently being evaluated in Phase 2 trials for this condition 2.

For the clinician treating this condition

  • Brolucuzumab (6 mg IVT) and RN6G have been established in clinical trial settings for retinal degeneration [1, 3, 5].
  • RN6G administration is associated with measurable changes in plasma Amyloid (A) Beta concentrations and stable Prothrombin Time (PT) INR levels 3.

AI synthesis of 3 cited trials, updated Jun 27, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.